Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure

American Journal of Cardiology

Volumn 84, Issue 9, 1999, Pages 1038-1043

  Guazzi, Marco ^a   Palermo, Pietro ^a   Pontone, Gianluca ^a   Susini, Francesca ^a   Agostoni, Piergiuseppe ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ENALAPRIL; LOSARTAN; NORADRENALIN; PLACEBO;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; EXERCISE; FEMALE; HUMAN; HYPOTENSION; LUNG FUNCTION; MALE; NORADRENALIN BLOOD LEVEL; OXYGEN CONSUMPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG SYNERGISM; ENALAPRIL; EXERCISE TEST; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; LOSARTAN; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; RECEPTORS, ANGIOTENSIN; TREATMENT OUTCOME;

EID: 0032745106     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00495-6     Document Type: Article

References (30)

1. Mancini D.M., Eisen H., Kussmaul W., Mull R., Edmunds L.H. Jr, Wilson J.R. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 83:1991;778-786.
2. Wasserman K. Diagnosing cardiovascular and lung pathophysiology from exercise gas exchange. Chest. 112:1997;1091-1101.
3. Drexler H. Endothelium as a therapeutic target in heart failure. Circulation. 98:1998;2652-2655.
4. Guazzi M., Marenzi G.C., Alimento M., Contini M., Agostoni P.G. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation. 95:1997;1930-1936.
5. Guazzi M., Pontone G., Agostoni P.G. Aspirin worsens exercise performance and pulmonary gas exchange in heart failure patients who are taking ACE-inhibitors. Am Heart J. 138:1999;254-259.
6. Spinale F.G., de Gasparo M., Whitebread S., Hebbar L., Clair M.J., Melton M., Krombach R.S., Mukherjee R., Iannini J.P., Seung-Jun O. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure. I. Effects on left ventricular performance and neurohumoral systems. Circulation. 96:1997;2385-2396.
7. Azizi M., Chatellier G., Guyene T.T., Murieta-Geoffroy D., Menard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium depleted normotensives. Circulation. 92:1995;825-834.
8. Hamroff G., Blaufarb I., Mancini D., Katz S.D., Bijou R., Olivari M.T., Thomas S., LeJemtel T.H. Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure. J Cardiovasc Pharmacol. 30:1997;533-536.
9. Cohn J.N., Johnson G.R., Shabetai R., Loeb H., Tristani F., Rector T., Smith R., Fletcher R. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation. 87:(suppl VI):1993;VI-5-VI-16.
10. Roughton F.J.W., Forster F.E. Relative importance of diffusion and chemical reaction rates in determining rate of exchange of gases in human lung, with special reference to true diffusing capacity of blood in the lung capillaries. J Appl Physiol. 11:1957;290-302.
11. Cotes J.E., Dabbs J.M., Elwood P.C., Hall A.M., McDonald A., Saunders M.J. Iron deficiency anemia its effect on transfer factor for the lung (diffusing capacity) and ventilation and cardiac frequency during submaximal exercise . Clin Sci. 42:1972;325-335.
12. Knudson R.J., Lebowitz M.D., Holberg C.J., Burrow B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Resp Dis. 127:1983;725-734.
13. Myers J., Froelicher V.F. Optimizing the exercise test for pharmacological investigations. Circulation. 82:1990;1839-1846.
14. Wasserman K. Coupling of external to cellular respiration during exercise the wisdom of the body revisited . Am J Physiol. 266:1994;E519-E539.
15. Rector T.S., Kubo S.H., Cohn J.N. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol. 71:1993;1106-1107.
16. Weber K.T., Janicki J.S. Cardiopulmonary exercise testing for evaluation of chronic cardiac failure. Am J Cardiol. 55:(suppl.):1985;22A-31A.
17. Itoh H., Taniguchi K., Koike A., Doi M. Evaluation of severity of heart failure using ventilatory gas analysis. Circulation. 80:(suppl II):1990;II-31-II-37.
18. Chua T.P., Ponikowski P., Harrington D., Anker S.D., Webb-Peploe K., Clark A.L., Poole-Wilson H., Coats A.J. Clinical correlates and prognostic significance of the ventilatory response in chronic heart failure. J Am Coll Cardiol. 29:1997;1585-1590.
19. Stevenson L.W., Steimle A.E., Fonarow G., Kermani D., Hamilton M.A., Morigushi J.D., Walden J., Tillisch J.H., Drinkwater D.C. Improvement in exercise capacity of candidates awaiting heart transplantation. J Am Coll Cardiol. 25:1995;163-170.
20. Lang R.M., Elkayam U., Yellen L.G., Krauss D., McKelvie R.S., Vaughan D.E., Ney D.E., Makris L., Chang P.I. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. J Am Coll Cardiol. 30:1997;983-991.
21. Guazzi M., Melzi G., Agostoni P.G. Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 80:1997;1572-1576.
22. Vescovo G., Dalla Libera L., Serafini F., Leprotti C., Facchin L., Volterrani M., Ceconi C., Ambrosio G.B. Improved exercise tolerance after losartan and enalapril in heart failure. Correlation with changes in skeletal muscle heavy chain composition. Circulation. 98:1998;1742-1749.
23. Guazzi M., Agostoni P.G. ACE-inhibition restores the diffusing capacity to carbon monoxide in chronic heart failure patients by improving the molecular diffusion across the alveolar-capillary membrane. Clin Sci. 96:1999;17-22.
24. Wasserman K., Zhang Y.Y., Gitt A., Belardinelli R., Koike A., Lubarski L., Agostoni P.G. Lung function and exercise gas exchange in chronic heart failure. Circulation. 96:1997;2221-2227.
25. Wilson J.R., Ferraro N. Effect of the renin-angiotensin system on limb circulation and metabolism during exercise in patients with heart failure. Am J Cardiol. 6:1985;56-63.
26. Hollenberg N.K., Fisher N.D.L., Price D.A. Pathways for angiotensin II generation in intact human tissue. Evidence from comparative pharmacological interruption of the renin system. Hypertension. 32:1998;387-392.
27. Drexler H., Banhardt U., Meinertz T., Wollschlager H., Lehmann M., Just H. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind placebo-controlled trial. Circulation. 79:1989;491-502.
28. Hornig B., Arakawa N., Haussmann D., Drexler H. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation. 98:1998;2842-2848.
29. Pitt B., Segal R., Martinez F.A., Meurers G., Cowley A.J., Thomas I., Deedwania P.C., Ney D.E. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly Study, ELITE). Lancet. 349:1997;747-752.
30. Guazzi M., Melzi G., Marenzi G.C., Agostoni P.G. ACE-inhibition facilitates alveolar-capillary gas transfer, and improves ventilation/perfusion coupling in patients with left ventricular dysfunction. Clin Pharmacol Therap. 65:1999;319-327.